This observation was corroborated by a recent study of the key role of ZAK in promoting the epithelial–mesenchymal transition in cancer progression, which showed that ZAK overexpression is significantly associated with poor survival in a number of human cancer types including breast cancer.31 In the TNBC subset of breast cancer patients (n = 117), the TP53 mutation frequency and the AURKB gene expression were found to be significantly higher compared to non-TNBC patients (Wilcoxon rank sum two-sided test, p < 0.0001). This evidence concerns the gene MAP3K20 and breast cancer.